



GENFIT TO PRESENT AT THE 2010 BIO INTERNATIONAL CONVENTION IN CHICAGO

Lille (France), Cambridge (Massachusetts, United States), April 29th, 2010 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces its participation and presentation at the BIO International Convention in Chicago (May 3-6, 2010).

During this event, the Company will meet with Mme Anne-Marie Idrac, the French Secretary of State for Foreign Trade, at the French Pavilion on May 4th, under the auspices of the “Nutrition Health Longevity” competitive cluster. GENFIT will also present later the same day at the BIO Business Forum.

Jean-François Mouney, Chairman of GENFIT’s Management Board, stated: “BIO is the essential annual business convention for the strengthening of our ties with major R&D teams, both from academia and from the pharmaceutical industry. This year again, we are proud to present the recent clinical data from our therapeutic programs, and also the latest developments for our biomarkers program dedicated to the early detection of diabetes.”

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neurodegenerative disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, Alzheimer’s...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health concerns and their unmet medical needs. GENFIT’s proprietary research programs and its partnerships with leading pharmaceutical companies, including SANOFI-AVENTIS, SOLVAY GROUP, and SERVIER, have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and two other compounds, in partnership with SANOFI-AVENTIS and SOLVAY, are in the advanced stages of Phase I.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 120 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – Chairman of the Management Board
+33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr